All In Biotech

Drug Trial Radar · NCT06643780

RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis

RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 9, 2024

Primary completion

Apr 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Prince of Wales Hospital, Shatin, Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chinese University of Hong Kong
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.

Conditions

  • Sarcopenia in Elderly

Interventions

  • DenosumabDrug

    60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

  • Zolendronic AcidDrug

    5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6-metre walkTime frame: From enrollment to the end of treatment at 52 weeks
  2. 5-time chair stand testTime frame: From enrollment to the end of treatment at 8 weeks
  3. Appendicular skeletal muscle mass (ASM)Time frame: From enrollment to the end of treatment at 52 weeks
  4. Handgrip strengthTime frame: From enrollment to the end of treatment at 52 weeks
  5. Quadriceps muscle strengthTime frame: From enrollment to the end of treatment at 52 weeks
  6. Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks
  7. Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks
  8. Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks
  9. Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks
  10. Balancing abilityTime frame: From enrollment to the end of treatment at 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Chinese University of Hong Kong

    Hong Kong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.